Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
Immune checkpoint blockade (ICB) therapies have significantly improved the prognosis and shown considerable promise for cancer therapy; however, differences in ICB treatment efficacy between the elderly and young are unknown. We analyzed the studies enrolled in the meta-analysis using the deft appro...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.657575/full |
| _version_ | 1818956735631589376 |
|---|---|
| author | Qi-jie Zhang Jiao-chen Luan Le-bin Song Rong Cong Cheng-jian Ji Xiang Zhou Jia-dong Xia Ning-hong Song Ning-hong Song |
| author_facet | Qi-jie Zhang Jiao-chen Luan Le-bin Song Rong Cong Cheng-jian Ji Xiang Zhou Jia-dong Xia Ning-hong Song Ning-hong Song |
| author_sort | Qi-jie Zhang |
| collection | DOAJ |
| description | Immune checkpoint blockade (ICB) therapies have significantly improved the prognosis and shown considerable promise for cancer therapy; however, differences in ICB treatment efficacy between the elderly and young are unknown. We analyzed the studies enrolled in the meta-analysis using the deft approach, and found no difference in efficacy except melanoma patients receiving anti–PD-1 therapy. Similarly, higher treatment response rate and more favorable prognosis were observed in elderly patients in some cancer types (e.g., melanoma) with data from published ICB treatment clinical trials. In addition, we comprehensively compared immunotherapy-related molecular profiles between elderly and young patients from public trials and The Cancer Genome Atlas (TCGA), and validated these findings in several independent datasets. We discovered a divergent age-biased immune profiling, including the properties of tumors (e.g., tumor mutation load) and immune features (e.g., immune cells), in a pancancer setting across 27 cancer types. We believe that ICB treatment efficacy might vary depending on specific cancer types and be determined by both the tumor internal features and external immune microenvironment. Considering the high mutational properties in elderly patients in many cancer types, modulating immune function could be beneficial to immunotherapy in the elderly, which requires further investigation. |
| first_indexed | 2024-12-20T10:58:41Z |
| format | Article |
| id | doaj.art-e2ec57dc874d4b3ca38da32524a85d52 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T10:58:41Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e2ec57dc874d4b3ca38da32524a85d522022-12-21T19:43:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-04-011210.3389/fimmu.2021.657575657575Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade TherapyQi-jie Zhang0Jiao-chen Luan1Le-bin Song2Rong Cong3Cheng-jian Ji4Xiang Zhou5Jia-dong Xia6Ning-hong Song7Ning-hong Song8Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The Affiliated Kezhou People’s Hospital of Nanjing Medical University, Xinjiang, ChinaImmune checkpoint blockade (ICB) therapies have significantly improved the prognosis and shown considerable promise for cancer therapy; however, differences in ICB treatment efficacy between the elderly and young are unknown. We analyzed the studies enrolled in the meta-analysis using the deft approach, and found no difference in efficacy except melanoma patients receiving anti–PD-1 therapy. Similarly, higher treatment response rate and more favorable prognosis were observed in elderly patients in some cancer types (e.g., melanoma) with data from published ICB treatment clinical trials. In addition, we comprehensively compared immunotherapy-related molecular profiles between elderly and young patients from public trials and The Cancer Genome Atlas (TCGA), and validated these findings in several independent datasets. We discovered a divergent age-biased immune profiling, including the properties of tumors (e.g., tumor mutation load) and immune features (e.g., immune cells), in a pancancer setting across 27 cancer types. We believe that ICB treatment efficacy might vary depending on specific cancer types and be determined by both the tumor internal features and external immune microenvironment. Considering the high mutational properties in elderly patients in many cancer types, modulating immune function could be beneficial to immunotherapy in the elderly, which requires further investigation.https://www.frontiersin.org/articles/10.3389/fimmu.2021.657575/fullimmune checkpoint blockadeageimmune profilestherapy efficacyimmunotherapy |
| spellingShingle | Qi-jie Zhang Jiao-chen Luan Le-bin Song Rong Cong Cheng-jian Ji Xiang Zhou Jia-dong Xia Ning-hong Song Ning-hong Song Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy Frontiers in Immunology immune checkpoint blockade age immune profiles therapy efficacy immunotherapy |
| title | Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy |
| title_full | Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy |
| title_fullStr | Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy |
| title_full_unstemmed | Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy |
| title_short | Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy |
| title_sort | age related differences in molecular profiles for immune checkpoint blockade therapy |
| topic | immune checkpoint blockade age immune profiles therapy efficacy immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.657575/full |
| work_keys_str_mv | AT qijiezhang agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT jiaochenluan agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT lebinsong agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT rongcong agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT chengjianji agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT xiangzhou agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT jiadongxia agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT ninghongsong agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy AT ninghongsong agerelateddifferencesinmolecularprofilesforimmunecheckpointblockadetherapy |